The results showed that CAR-CD133 T-cell therapy was feasible and had controllable toxicities; 3 patients achieved partial remission (including 1 HCC patient), and 14 patients (including 9 HCC patients) acquired stable disease; the 3-month disease control rate was 65.2%, and the median progression-free survival was 5 months 154. The gene discussed is PROM1; the disease is hepatocellular carcinoma.